Catalyst Pharmaceuticals, Inc. (CPRX)
Automate Your Wheel Strategy on CPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including CPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CPRX
- Rev/Share 4.7161
- Book/Share 7.506
- PB 3.1188
- Debt/Equity 0.0027
- CurrentRatio 6.6218
- ROIC 0.2135
- MktCap 2877315328.0
- FreeCF/Share 1.9131
- PFCF 12.2678
- PE 13.1919
- Debt/Assets 0.0023
- DivYield 0
- ROE 0.2639
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CPRX | Robert W. Baird | -- | Outperform | -- | $28 | Feb. 4, 2025 |
News
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi's 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025.
Read More
CPRX vs. ZTS: Which Stock Is the Better Value Option?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Read More
Wall Street Analysts Believe Catalyst (CPRX) Could Rally 51.45%: Here's is How to Trade
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 51.5% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
Read More
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Director William T.
Read More
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Read More
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Read More
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Read More
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
About Catalyst Pharmaceuticals, Inc. (CPRX)
- IPO Date 2006-11-08
- Website https://www.catalystpharma.com
- Industry Biotechnology
- CEO Richard John Daly
- Employees 181